QTc Prolongation Risk Evaluation in Female COVID-19 Patients Undergoing Chloroquine and Hydroxychloroquine With/Without Azithromycin Treatment
- 1Pharmacovigilance, ContraRx, NJ, United States Edison, NJ, United States
- 2NYU Langone Health, New York University School of Medicine, New York, NY, United States
- 3Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht, Netherlands
- 4Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Médecine—Intensive Réanimation, Lyon, France
- 5Women's Health Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, United States
- 6Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, United States
Women have higher risk for developing TdP in response to ventricular repolarization prolonging drugs. Hundreds of trials are administering chloroquine and hydroxychloroquine with/without azithromycin to COVID-19 patients. While an overall prolonged QTc has been reported in COVID-19 patients undergoing these treatments, the question on even higher QTc elevation risk in thousands of female COVID-19 patients undergoing these treatments remains unanswered. We therefore explore data reported and shared with us to evaluate safety and efficacy of antimalaria pharmacotherapies in female COVID-19 patients. Although we observed longer mean QTc intervals in female patients in 2 of the 3 cohorts reviewed, the sex disproportionality in COVID-19 hospitalizations precludes a clear sex mediated QTc interval elevation risk association in the female COVID-19 patients undergoing acute treatment regimens. Adoption of study designs that include observation of sex mediated differential triggering of cardiac electrical activity by these drugs is warranted.
Female gender is a known risk factor for QTc prolongation and one of the highest pro-arrhythmic risk factors (1–3). Women are at a significantly greater risk than men for developing the potentially fatal ventricular arrhythmia torsades de pointes (TdP) in response to certain drugs that prolong ventricular repolarization (1, 4). TdP occurs three times more commonly in women than in men, and female gender is also an independent risk factor for the incidence of syncope and sudden death in the inherited long QT syndrome (LQTS) (5, 6).
In the current coronavirus disease 2019 (COVID-19) pandemic crisis, without validated treatment options available for management, hundreds of trials are administering chloroquine and hydroxychloroquine with/without azithromycin to COVID-19 patients in monitored settings, while associated benefits and risks remained debated. Chloroquine, hydroxychloroquine, and azithromycin are individually implicated in prolonging corrected heart rate (QTc), a predictor of TdP (7–10). Concurrent use of QTc altering drugs can result in synergistic increase in risk of ventricular arrhythmias and sudden death (11, 12), a setting recreated by the current COVID-19 treatment regimens.
Factors associated with increased QT prolongation cardiotoxicity risk in females include hormonal mediated differentiation in cardiac electrical activities, greater genetic predisposition for Long QT Syndrome (LQTS) and a higher propensity for drug acquired LQTS driven by drug-drug Interactions (13). The baseline QTc is longer in women than in men (14–16). Endogenous estrogen is associated with QTc lengthening, while testosterone and progesterone shorten the action potential (16, 17). Small QTc prolongation also has been reported with some fourth generation oral contraceptives (18). Women have a higher predisposition to genetic mutations that potentiate TdP and have a higher risk of TdP with Long QT syndrome (LQTS) type 1 and type 2, caused by mutations in potassium channel gene KCNQ1 (KvLQT1) and mutations in potassium channel gene KCNH2 (also known as hERG), respectively (19, 20).
Furthermore, female gender is increasingly recognized as an independent risk factor for acquired LQTS which mainly occurs on exposure to an environmental stressor, most common being an adverse drug reaction leading to drug induced LQTS (DI-LQTS). The mechanisms underlying QT prolongation by medications in acquired LQTS almost always involve blockage of the inward potassium rectifier (IKr) channel, also known as the human ether-a-go-go-related gene (hERG) channel (21). IKr channel controls the movement of potassium out of the myocytes and conducts a rapid IKr current, a critical current in the phase 3 repolarization of the cardiac action potential (22). LQTS and the QT interval prolongation relative to the administration of IKr blockers is greater in women and accompanied by a propensity of drug-induced polymorphic ventricular arrhythmia (5, 23). The estrogen-mediated reduced repolarization reserve in women is believed to be responsible for their higher susceptibility to DI-LQTS (5).
Although the higher risk in females is well-recognized, mechanisms underlying these sex-based risk differences are notably poorly understood. Using a combined experimental and computational approach using “male” and “female” computational model representations of human ventricular cardiac myocytes, a recent study provides first evidence linking structure to function mechanisms underlying higher risk for acquired long-QT-dependent arrhythmias in females (24). Structural modeling presented two distinct, plausible mechanisms of estrogen action enhancing torsadogenic effects: estradiol interaction with hERG mutations in the pore loop containing G604 or with common TdP-related blockers in the intra-cavity binding site. The model predicted increased risk for arrhythmia in females when acute sympathetic nervous system discharge was applied in the settings of both inherited and acquired long-QT syndrome.
Another study models prediction of potential cardiac adverse events caused by combination COVID-19 treatments by combining simulations of pharmacokinetics (PK) with quantitative systems pharmacology (QSP) modeling of ventricular myocytes (25). Their simulation results predicted that drug combinations can lead to greater cellular action potential prolongation compared to drugs given in isolation. The simulations of different patient groups also predicted that females with pre-existing heart disease are especially susceptible to drug-induced arrhythmias, compared males with disease or healthy individuals of either sex.
Despite the high cardiotoxicity risk associated with combination treatments of Chloroquine, hydroxychloroquine and azithromycin in female COVID-19 patients, clinical data supportive of this risk outcome is still not available. We provide first look at clinical QTc data elongation patterns in male vs. female COVID-19 patients from multiple clinical trials across different geographical regions.
Results and Discussion
With surveillance of the COVID-19 management interventions, studies are now reporting safety concerns, including the risk of QTc prolongation in patients receiving these treatments (Table 1). Re-iterating the predicate hypotheses, all these studies report clinically relevant QTc interval increase in COVID-19 patients receiving these pharmacotherapies and recommend continuous QTc interval monitoring and strict cutoffs for therapy cessation (9, 26–32). While an overall prolonged QTc is observed in COVID-19 patients undergoing these treatments, the question on even higher QTc elevation risk in thousands of female COVID-19 patients undergoing these treatments remains unanswered. We therefore look deeper into the data reported (28, 30) and additional data shared with us (9, 26, 27, 29, 31) to assess if sex mediated disparities in the QTc alterations exist in COVID-19 treatments.
In recent report from on New York and Italy COVID-19 patient cohort, Chorin et al. (9, 29) reported significantly prolonged QTc intervals in COVID-19 patients treated with hydroxychloroquine and azithromycin. Additional data shared with us on a cohort of 251 patients shows that the average baseline QTc in male patients was 441 ± 30 ms while maximum QTc during treatment (QTc max) was 476 ± 36 ms (Table 2A). For the female patients, mean baseline QTc of 438 ± 26 and QTc max of 468 ± 38 were observed. This translates into an average increase of 35 ms in the male patients and 30 ms in female patients after treatment with hydroxychloroquine and azithromycin. Sample QTc elevation illustrations in two female patients are shown (Table 2D).
Another retrospective, observational cohort conducted on 95 COVID-19 patients in Netherlands also reported clinically relevant prolonged QTc intervals in patients undergoing chloroquine therapy (26). Additional data shared with us reveals that female patients made up 34% of the cohort and their average baseline QTc of 438 ms (346–514) was elevated to 476 ms (415–600) post-chloroquine administration (manual interpretation). In male patients, a baseline mean QTc of 429 ms (369–609) increased to 461 ms (385–557) post-treatment. An increase of 32 ms in male patients (n = 63) and 38 ms in female patients (n = 32) was recorded during chloroquine treatment (Table 2B). Eight of 32 females (25%) had a QTC > 500 ms post-chloroquine vs. 14 of 64 males (22%).
Recent publication by Bessière et al. (31) on data from 49 COVID-19 ICU patients in France reveals QTc interval increase in 93% patients after the administration of the antiviral therapy with hydroxychloroquine alone or in combination with azithromycin. The overall median baseline QTc was 414 ms and max QTc after antiviral therapy was 454 ms. This cohort include 20% female patients and a 52 ms mean increase was observed in their baseline QTc average of 411 ± 26 ms to a maximal average value of 463 ± 29 during treatment. The baseline QTc average of 413 ± 30 in males was elevated to 452 ± 45 after treatment (Table 2C). None of the female patients showed QTc >500 ms.
Data from New York state department of health retrospective cohort of 1,438 patients hospitalized COVID-19 patients treatment with hydroxychloroquine, azithromycin, or both, indicated that cardiac arrest was more likely in patients receiving hydroxychloroquine and azithromycin, compared to hydroxychloroquine alone and azithromycin alone (27). Additional data (personal communication) on male and female patient distribution revealed QTc prolongation was observed in 13.0% male and 12.0% female patients in the HCQ and azithromycin cohort. In the HCQ alone cohort prolongation was observed in 16.8% males and 16.7% female patients. For the azithromycin alone cohort, they observed 7.8% percent prolongation in males and 9.2% prolongation in female patients and in the no treatment cohort, 11.7% prolongation in males and 5.1% prolongation in female patients.
Although we observed longer mean QTc intervals in female patients in 2 of the 3 cohorts reviewed, no conclusive sex mediated QTc interval elongation is apparent amongst the COVID-19 patients undergoing acute chloroquine and hydroxychloroquine with/without azithromycin treatment regimens (9, 26, 27, 29, 31). Since a greater proportion of COVID-19 patients admitted to the hospitals are males, the sex disproportionality in hospitalizations precludes a distinctive risk association in the female COVID-19 patients (27). None of the studies included had an outcome measure of investigating sex mediated differential QTc response in COVID-19 patients and given the diverse study designs, our retrospective, observational analysis lacks statistical validation. Additionally, the results could also be skewed by co-consumption of other medications and underlying co-morbidities. While validation from optimally designed trials is still required, adoption of study designs that include observation of sex mediated differential triggering of cardiac electrical activity by these drugs is warranted.
SG: research and writing. LJ: data from NYC COVID-19 trial. MB: data form Netherlands COVID-19 trial. MC: data from France COVID 19 trial. GB: women health contribution. JK: cardiology contribution. KM: project conception, coordination, and writing. All authors contributed to the article and approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
We are thankful to Eli S. Rosenberg and Tomoko Udo, State University of New York, Rensselaer, for generously sharing data from the New York state department of health retrospective cohort of COVID-19 patients (27). We also acknowledge Vitali Coltuclu for his help with data analytics.
CQ, Chloroquine; HCQ, Hydroxychloroquine; AZ, Azithromycin; Os, Oseltamivir; ms, milliseconds; ΔQTc, Change in corrected QT interval; VT, Polymorphic ventricular tachycardia; TdP, torsades de pointes; Rx, Drug; Red., Reduction in dose; Term., Termination.
1. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. (1993) 270:2590–7. doi: 10.1001/jama.1993.03510210076031
2. Bednar MM, Harrigan EP, Ruskin JN. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol. (2002) 89:1316–9. doi: 10.1016/S0002-9149(02)02337-8
6. Darpo B, Karnad DR, Badilini F, Florian J, Garnett CE, Kothari S, et al. Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol. Br J Clin Pharmacol. (2014) 77:522–31. doi: 10.1111/bcp.12201
7. Projean D, Baune B, Farinotti R, Flinois JP, Beaune P, Taburet AM, et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. (2003) 31:748–54. doi: 10.1124/dmd.31.6.748
8. Hancox JC, Hasnain M, Vieweg WVR, Crouse ELB, Baranchuk A. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports. Ther Adv Infect Dis. (2013) 1:155–65. doi: 10.1177/2049936113501816
9. Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with Hydroxychloroquine/Azithromycin. Heart Rhythm. (2020). doi: 10.1016/j.hrthm.2020.05.014. [Epub ahead of print].
13. Misra K. Drug induced QT interval prolongation risk factors for female patients undergoing current treatments for COVID-19. CV Network. (2020) 19:12–36. Available online at: https://0901.nccdn.net/4_2/000/000/076/de9/CV-Network-Vol-19-No-1-March-2020.pdf
16. Nakagawa M, Ooie T, Takahashi N, Taniguchi Y, Anan F, Yonemochi H, et al. Influence of menstrual cycle on QT interval dynamics. Pacing Clin Electrophysiol. (2006) 29:607–13. doi: 10.1111/j.1540-8159.2006.00407.x
17. Saito T, Ciobotaru A, Bopassa JC, Toro L, Stefani E, Eghbali M. Estrogen contributes to gender differences in mouse ventricular repolarization. Circ Res. (2009) 105:343–52. doi: 10.1161/CIRCRESAHA.108.190041
18. Sedlak T, Shufelt C, Iribarren C, Lyon LL, Noel Bairey Merz C. Oral contraceptive use and the ECG: evidence of an adverse QT effect on corrected QT interval. Ann Noninvasive Electrocardiol. (2013) 18:389–98. doi: 10.1111/anec.12050
19. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. (2000) 102:1178–85. doi: 10.1161/01.CIR.102.10.1178
20. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. (2001) 103:89–95. doi: 10.1161/01.CIR.103.1.89
24. Yang Z, Prinsen JK, Bersell KR, Shen W, Yermalitskaya L, Sidorova T, et al. Azithromycin causes a novel proarrhythmic syndrome. circulation. Arrhythm Electrophysiol. (2017) 10. doi: 10.1161/CIRCEP.115.003560
25. Varshneya M, Irurzun-Arana I, Campana C, Dariolli R, Gutierrez A, Pullinger TK, et al. Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions. medRxiv. [Preprint] (2020). doi: 10.1101/2020.05.21.20109397
26. van den Broek MP, Möhlmann JE, Abeln BG, Liebregts M, van Dijk VF, van de Garde EM. Chloroquine-induced QTc prolongation in COVID-19 patients. Neth Heart J. (2020) 28:406–9. doi: 10.1007/s12471-020-01429-7
27. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. (2020) 323:2493–502. doi: 10.1001/jama.2020.8630
28. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. (2020). doi: 10.1001/jamacardio.2020.1834. [Epub ahead of print].
29. Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med. (2020) 26:808–9. doi: 10.1038/s41591-020-0888-2
30. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. (2020) 3:e208857. doi: 10.1001/jamanetworkopen.2020.8857
31. Bessière F, Roccia H, Delinière A, Charrière R, Chevalier P, Argaud L, et al. Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. (2020) 1:e201787. doi: 10.1001/jamacardio.2020.1787
Keywords: COVID, QTc changes, hydroxychloroquine, chloroquin, azithromycin (AZM), QTc, hydroxychloroquine (HCQ), women
Citation: Grewal S, Jankelson L, van den Broek MPH, Cour M, Bachmann G, Kostis JB and Misra K (2020) QTc Prolongation Risk Evaluation in Female COVID-19 Patients Undergoing Chloroquine and Hydroxychloroquine With/Without Azithromycin Treatment. Front. Cardiovasc. Med. 7:152. doi: 10.3389/fcvm.2020.00152
Received: 10 June 2020; Accepted: 22 July 2020;
Published: 02 September 2020.
Edited by:Andrew F. James, University of Bristol, United Kingdom
Reviewed by:Pedro Brugada, Independent Researcher, Brussels, Belgium
Eric A. Sobie, Icahn School of Medicine at Mount Sinai, United States
Copyright © 2020 Grewal, Jankelson, van den Broek, Cour, Bachmann, Kostis and Misra. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kamana Misra, Kamana@contrarx.com